WASHINGTON, DC (July 2, 2020) — AAM and its Biosimilars Council commend Senators Cornyn and Bennet for introduction of the Increasing Access to Biosimilars Act. This bipartisan proposal is based on a simple idea – that Medicare policies should encourage the use of the most effective, lowest-cost medicine. Biosimilars consistently deliver savings compared to high-priced brand biologics. We encourage Congress and the Administration to quickly implement this policy and deliver savings to America’s patients and taxpayers.
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 22 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.